| Oct 21 |
Gilead upgraded to outperform by Leerink on PrEP outlook
|
| Oct 21 |
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
|
| Oct 19 |
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
|
| Oct 19 |
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
|
| Oct 19 |
Notable analyst calls this week: Etsy, Zoom and Enphase among top picks
|
| Oct 18 |
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
|
| Oct 18 |
Gilead to pull Trodelvy U.S. indication on trial setback
|
| Oct 18 |
Gilead withdraws bladder cancer drug in US after failed trial
|
| Oct 18 |
High Growth Tech Stocks to Watch in October 2024
|
| Oct 17 |
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
|
